-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test is an affordable, accessible blood test that detects cancer in dogs.

A spotlight on… Volition’s U.S. Clinical Product Strategy
- Share
- Tweet
- Share on Facebook
- Share
Sharon was appointed as U.S. Head of Quality and Development Process in April 2022.
Bringing over 20 years of experience within the in vitro diagnostic industry to Volition, Sharon was excited to join the company at such a pivotal stage.
What has she been up to since joining Volition? Find out in the video below.

Stay in touch
To stay up to date with our developments, sign up to our email alerts, and follow Volition on LinkedIn, Twitter, Facebook, or follow our dedicated Volition Veterinary LinkedIn account.
Related Articles
-
Press Releases
VolitionRX Limited: Outlines broad strategy to become the “NETs company” worldwide through licensing and updates progress of Nu.Q® NETs test adoption
-
Press Releases
VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets
- Share
- Tweet
- Share on Facebook
- Share
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields